Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Goodwin says it advises Marea on Lisata acquisition alongside $225 million financing
Goodwin announced that it had advised Marea Therapeutics on its acquisition by Lisata Therapeutics. The firm said Lisata also entered an agreement for a private placement expected to raise approximately $225 million before expenses, and described the acquisition as a stock-for-stock transaction involving the companies’ biotechnology businesses.
Key points
- Goodwin said the financing involved Series C nonvoting convertible preferred stock.Goodwin Procter
- The announcement identified RA Capital, Forbion and Third Rock Ventures among participating investors.Goodwin Procter
- The firm said Marea’s MAR001 candidate was in Phase 2b development for severe hypertriglyceridemia.Goodwin Procter
- Goodwin named Blake Liggio, Richard Schwartz and Maggie Wong as team leaders.Goodwin Procter